By IDSE News Staff
The CDC recommended a new passive immunization starting this fall to help protect all infants younger than 8 months and some older infants at increased risk for severe illness caused by respiratory syncytial virus (RSV).
CDC Director Mandy Cohen, MD, MPH, adopted the recommendation of the CDC Advisory Committee on Immunization Practices (ACIP) for the use of nirsevimab (Beyfortus, AstraZeneca), a long-acting monoclonal antibody product, which has been shown to reduce the risk